SPECIAL SECTION ON DRUG METABOLISM AND REGULATION

Editorial. Xiao-bo Zhong and Yurong Lai ............... 998
Perspective of the Induction of Liver Microsomal Cytochrome P450s by Chemical Compounds. Tsuneo Omura ......... 1000
Searching for Constitutive Androstane Receptor Modulators. Pauvo Honkasalo ............... 1002
Clinical Relevance of the Constitutive Androstane Receptor. Sydney Stern, Ritika Kurian, and Hongbing Wang ............... 1010
Distinct Roles of the Sister Nuclear Receptors PXR and CAR in Liver Cancer Development. Kouichi Yoshinari and Ryo Ishitani ............... 1019
From Steroid and Drug Metabolism to Glycobiology, Using Sulfotransferase Structures to Understand and Tailor Function. Lars C. Pedersen, Myeong Jin Yi, Lee G. Pedersen, and Andrea M. Kaminski ............... 1027

ARTICLES

Target-Mediated Drug Disposition Affects the Pharmacokinetics of Interleukin-10 Fragment Crystallizable Fusion Proteins at Pharmacologically Active Doses. Zheng Yang, Surenendran Rajendran, Vanessa Spires, Brian Poisson, Murali Gururajan, Zheng Lin, Jaren Arbanas, Stanley Krystek, James Loy, Yuan Cheng, Stephen Carl, Samantha Pace, Yun Wang, John Mehl, Shihua Xu, Krishna Vasudevan, Miranda Broz, Lois Lehman-McKeeman, Paul Morin, and Robert F. Graziano ............... 998
Selection of an Optimal In Vitro Model to Assess P-gp Inhibition: Comparison of Vesicular and Bidirectional Transcellular Transport Inhibition Assays. Jocelyn Yabut, Robert Houle, Shubing Wang, Andy Liow, Ravi Katwaru, Hannah Collier, Lucinda Hittle, and Xiuyan Chu ............... 909
The Hydroxylation Position Rather than Chirality Determines How Efavirenz Metabolites Activate Cytochrome P450 46A1 In Vitro. Natalia Mast, Anna fotinich, and Irina A. Pikuleva .......... 923
Metabolic Activation of the Acrylamide Michael Acceptor Warhead in Futibatinib to an Epoxide Intermediate Engenders Covalent Inactivation of CYP3A. Lloyd Wei Tat Tang, Jiexin Fu, Siew Kwan Koh, Guoyi Wu, Lei Zhou, and Eric Chun Yong Chan .......... 931
Regulation of Blood-Brain Barrier Transporters by Transforming Growth Factor-β/Activin Receptor-Like Kinase 1 Signaling: Relevance to the Brain Disposition of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors (i.e., Statins). Robert D. Beterton, Wazir Abdullahi, Erica I. Williams, Jeffrey J. Lochhead, Hrvoje Brzica, Joshua Stanton, Elizabeth Redell, Chidinma Ogbonna, Thomas P. Davis, and Patrick T. Ronaldson .......... 942
Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models. Yuli Qian and John S. Markowitz .......... 968
Sinusoidal Uptake Determines the Hepatic Clearance of Pevonedistat (TAK-924) as Explained by Extended Clearance Model. Philip Sandoval, Bei-Ching Chuang, Lawrence Cohen, Tomoki Yoneyama, Sandeepraj Pasalkar, Robert W. Yucha, Swapun K Chowdhury, and Parsh P. Chothe .......... 980
Metabolism and Disposition of [14C]Pevonedistat, a First-in-Class NEDD8-Activating Enzyme Inhibitor, after Intravenous Infusion to Patients with Advanced Solid Tumors. Jayaprakasam Bolleddula, Hao Chen, Lawrence Cohen, Xiaofei Zhou, Sandeepraj Pasalkar, Allison Berger, Farhad Sedarati, Karthik Venkatakrishnan, and Swapan K. Chowdhury. 989

Isotretinoin and its Metabolites Alter mRNA of Multiple Enzyme and Transporter Genes In Vitro, but Downregulation of Organic Anion Transporting Polypeptide Does Not Translate to the Clinic. Aprajita S. Yadav, Faith Stevison, Mika Kosaka, Susan Wong, Jane R. Kenny, John K. Amory, and Nina Isoherranen 1042

Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: The diverse biological function of CAR. See the article by Stern et al. (dx.doi.org/10.1124/dmd.121.000483).